About David Burgstahler
David Burgstahler is a director at ACP Ulysses.
David Burgstahler reports to the SEC as a director, officer or major shareholder of 8 public companies, including Organogenesis Holdings (ORGO), OmniAb (OABI) and RVL Pharmaceuticals plc (RVLP).
David Burgstahler first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name David Burgstahler in the role, so the role may have started earlier or lasted longer.
OI
Organogenesis Holdings Inc.
President & CEO, director
2016 – 2024 · Public company (ORGO)
OI
OmniAb, Inc.
President, CEO and director
2021 – 2024 · Public company (OABI)
RP
RVL Pharmaceuticals plc
Director and 10% owner
2018 – 2023 · Public company (RVLP)
WI
WideOpenWest, Inc.
Director and 10% owner
2017 – 2019 · Public company (WOW)
LI
Lantheus Holdings, Inc.
Director and 10% owner
2015 – 2017 · Public company (LNTH)
SI
Syneos Health, Inc.
Director and 10% owner
2014 – 2017 · Public company (SYNH)
AI
Angiodynamics Inc.
Director and 10% owner
2012 – 2017 · Public company (ANGO)
WP
Warner Chilcott plc
Director
2006 – 2009 · Public company (WCRX)
Key Colleagues at Startups
The people David Burgstahler works with at each company, as listed on that company's latest Form D.
ACP Ulysses Holdings, Inc. · Form D/A, Feb 9, 2026
NF
Neil Ferguson
Director
BH
Brett Huselton
Executive officer
RG
Robert Girardi
Director
MH
Michael Haratz
Executive officer
BB
Bekki Brown
Executive officer and director
EZ
Eddie Zhao
Director
KT
Karen Turner
Chief Financial Officer
CH
Charles Harwood
Director